Meghan Fitzgerald
Director at Roivant Sciences Ltd. (ROIV)
Purchase track record
Not enough history. Based on 0 purchases with a full 90 days of price history.
—
Avg. 90-day return—
vs. S&P 500—
Beat the market—
Paper profit on buys$0
Total bought / sold$0 / $3.3M
Reported trades
| Filed | Stock | Type | Shares | Price | Value | Since |
|---|---|---|---|---|---|---|
| Sep 17SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 4,71236,508 held (−11%) | $39.68 | $187K | -10.7% |
| Sep 17SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 40036,108 held (−1%) | $40.45 | $16K | -12.4% |
| Sep 10SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 20,00042,963 held (−32%) | $39.90 | $798K | -11.2% |
| Jul 2SEC | ROIVRoivant Sciences Ltd. | Sell Plan | 10,00042,963 held (−19%) | $34.90 | $349K | +1.5% |
| Mar 30SEC | ROIVRoivant Sciences Ltd. | Sell | 70,00042,963 held (−62%) | $27.45 | $1.9M | +29.1% |
- Sell
Director Meghan Fitzgerald sold $187K of ROIV at $39.68 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Meghan Fitzgerald sold $16K of ROIV at $40.45 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Meghan Fitzgerald sold $798K of ROIV at $39.90 — cuts the stake by 32%; pre-scheduled 10b5-1 plan sale.
- Sell
Director Meghan Fitzgerald sold $349K of ROIV at $34.90 — pre-scheduled 10b5-1 plan sale.
- Sell
Director Meghan Fitzgerald sold $1.9M of ROIV at $27.45 — cuts the stake by 62%.